Across TCGA pan-cancer cohorts, SFT2D1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SFT2D1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SFT2D1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SFT2D1 expression acts as an unfavorable survival marker.

PDAC, OV, and GBM are the cancer types where SFT2D1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.334	0.836	.010	14	view →
OV	DFS	Tertile	All	0.822	1.000	.041	8	view →
GBM	OS	Median	All	0.567	0.982	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SFT2D1 tumor-vs-normal RNA expression · all SFT2D1 data types